Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6539
    +0.0016 (+0.25%)
     

  • OIL

    84.11
    +0.54 (+0.65%)
     

  • GOLD

    2,358.10
    +15.60 (+0.67%)
     

  • Bitcoin AUD

    98,077.23
    +304.15 (+0.31%)
     

  • CMC Crypto 200

    1,383.82
    -12.71 (-0.91%)
     

  • AUD/EUR

    0.6097
    +0.0024 (+0.40%)
     

  • AUD/NZD

    1.0988
    +0.0030 (+0.28%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,118.95
    +40.09 (+0.50%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,060.20
    +142.92 (+0.80%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference

Oyster Point Pharma, Inc.

PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on Thursday, December 2, 2021. Presentations are available for registered attendees via the Piper Sandler conference site

About Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYA™ (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them. For more information, visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn.

Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com

Media Contact:
Sheryl Seapy
Real Chemistry
(213) 262-9390
sseapy@realchemistry.com